荃信生物 is a pioneering biopharmaceutical company that specializes in the development of clinical-stage biotherapeutics for autoimmune and allergic diseases. With a focus on addressing drug accessibility and affordability, the company is dedicated to finding innovative solutions in these areas through science and innovation. Established in 2015, 荃信生物 has a robust pipeline of nine investigational drugs, with 15 of them having obtained IND approval.

The